Suppr超能文献

通过靶向蛋白质组学鉴定阿尔茨海默病脑脊液中的纵向动态生物标志物。

Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.

机构信息

Department of Phamacodynamic Biomarkers within Development Sciences, Genentech, Inc, (a member of the Roche Group), 1 DNA Way, South San Francisco, CA 94080, USA.

出版信息

Mol Neurodegener. 2014 Jun 6;9:22. doi: 10.1186/1750-1326-9-22.

Abstract

BACKGROUND

Alzheimer's disease (AD) is the leading cause of dementia affecting greater than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ42, tau, and p-tau181 are well established as diagnostic biomarkers of AD, there is a need for additional CSF biomarkers of neuronal function that continue to change during disease progression and could be used as pharmacodynamic measures in clinical trials. Multiple proteomic discovery experiments have reported a range of CSF biomarkers that differ between AD and control subjects. These potential biomarkers represent multiple aspects of the disease pathology. The performance of these markers has not been compared with each other, and their performance has not been evaluated longitudinally.

RESULTS

We developed a targeted-proteomic, multiple reaction monitoring (MRM) assay for the absolute quantitation of 39 peptides corresponding to 30 proteins. We evaluated the candidate biomarkers in longitudinal CSF samples collected from aged, cognitively-normal control (n = 10), MCI (n = 5), and AD (n = 45) individuals (age > 60 years). We evaluated each biomarker for diagnostic sensitivity, longitudinal consistency, and compared with CSF Aβ42, tau, and p-tau181. Four of 28 quantifiable CSF proteins were significantly different between aged, cognitively-normal controls and AD subjects including chitinase-3-like protein 1, reproducing published results. Four CSF markers demonstrated significant longitudinal change in AD: Amyloid precursor protein, Neuronal pentraxin receptor, NrCAM and Chromogranin A. Robust correlations were observed within some subgroups of proteins including the potential disease progression markers.

CONCLUSION

Using a targeted proteomics approach, we confirmed previous findings for a subset of markers, defined longitudinal performance of our panel of markers, and established a flexible proteomics method for robust multiplexed analyses.

摘要

背景

阿尔茨海默病(AD)是导致全球 2600 多万人患有痴呆症的主要原因。虽然脑脊液(CSF)中 Aβ42、tau 和 p-tau181 的水平已被广泛确立为 AD 的诊断生物标志物,但仍需要其他 CSF 神经元功能生物标志物,这些标志物在疾病进展过程中持续变化,可作为临床试验中的药效学测量指标。多项蛋白质组学发现实验报告了 AD 患者和对照组之间存在差异的一系列 CSF 生物标志物。这些潜在的生物标志物代表了疾病病理学的多个方面。这些标志物的性能尚未相互比较,其性能也没有进行纵向评估。

结果

我们开发了一种靶向蛋白质组学、多重反应监测(MRM)测定法,用于绝对定量 39 个对应于 30 种蛋白质的肽段。我们评估了来自年龄较大、认知正常的对照组(n=10)、MCI(n=5)和 AD(n=45)个体(年龄>60 岁)的纵向 CSF 样本中的候选生物标志物。我们评估了每种生物标志物的诊断灵敏度、纵向一致性,并与 CSF Aβ42、tau 和 p-tau181 进行了比较。在年龄较大、认知正常的对照组和 AD 受试者之间,有 28 种可量化的 CSF 蛋白质中有 4 种存在显著差异,其中包括甲壳质酶-3 样蛋白 1,重现了已发表的结果。AD 中 4 种 CSF 标志物显示出显著的纵向变化:淀粉样前体蛋白、神经元五聚素受体、NrCAM 和嗜铬粒蛋白 A。在包括潜在疾病进展标志物在内的某些蛋白质亚组中观察到了稳健的相关性。

结论

使用靶向蛋白质组学方法,我们确认了先前部分标志物的发现结果,定义了我们标志物小组的纵向性能,并建立了一种灵活的蛋白质组学方法,用于稳健的多重分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a912/4061120/c2c092b14a34/1750-1326-9-22-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验